Anemia in patients with type 2 diabetes and renal failure

In this prospective cohort study, investigators evaluated and compared the incidence of anemia in 13,799 patients with type 2 diabetes and renal failure (stages 1-3), initiating treatment with SGLT2 inhibitors or GLP-1 analogues. After the median follow-up period of 2.5 years, patients treated with SGLT2 inhibitors had a lower incidence of anemia than patients treated with GLP1 analogues. However, treatment with SGLT2 inhibitors was not associated with a reduction in the number of anemia treatment initiations. SGLT2 inhibitors could be considered as an adjunctive therapy to reduce the incidence of anemia in this category of patients.